{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:20:07Z","timestamp":1782984007068,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clinthera.2019.10.008","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T11:22:37Z","timestamp":1573730557000},"page":"2549-2557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves"],"prefix":"10.1016","volume":"41","author":[{"given":"Vincenzo","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreina","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Attena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Golino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D'Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.10.008_bib1","first-page":"1467","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace: Eur Pacing Arrhythm Card Electrophysiol: J Working Groups Cardiac Pacing Arrhythmias Cardiac Cellular Electrophysiol Eur Soc Cardiol"},{"key":"10.1016\/j.clinthera.2019.10.008_bib2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.5603\/KP.2016.0172","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [in Polish]","volume":"74","author":"Kirchhof","year":"2016","journal-title":"Kardiologia Polska"},{"key":"10.1016\/j.clinthera.2019.10.008_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/jth.12500","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves: reply","volume":"12","author":"Eikelboom","year":"2014","journal-title":"J\u00a0Thromb Haemost : JTH"},{"key":"10.1016\/j.clinthera.2019.10.008_bib4","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2019.10.008_bib5","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1160\/TH16-11-0899","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2019.10.008_bib6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.10.008_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy)","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.10.008_bib8","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2019.10.008_bib9","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"69","author":"De Caterina","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2019.10.008_bib10","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American heart association task force on practice guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2019.10.008_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00392-015-0919-z","article-title":"Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves","volume":"105","author":"Yadlapati","year":"2016","journal-title":"Clin Res Cardiol : official J German Card Soc"},{"key":"10.1016\/j.clinthera.2019.10.008_bib12","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0037-1615261","article-title":"Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves\/prior surgical valve repair: a multicenter clinical practice experience","volume":"44","author":"Russo","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"13","key":"10.1016\/j.clinthera.2019.10.008_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","article-title":"Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves","volume":"135","author":"Carnicelli","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.10.008_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J\u00a0Thromb Haemost : JTH"},{"key":"10.1016\/j.clinthera.2019.10.008_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.10.008_bib16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2019.10.008_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/CIRCULATIONAHA.113.002927","article-title":"Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"128","author":"Steinberg","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2019.10.008_bib18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1160\/TH16-01-0007","article-title":"Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project","volume":"115","author":"Philippart","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2019.10.008_bib19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimaraes","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.clinthera.2019.10.008_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","article-title":"Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study","volume":"16","author":"Duraes","year":"2016","journal-title":"Drugs in R&D"},{"key":"10.1016\/j.clinthera.2019.10.008_bib21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7326\/0003-4819-155-9-201111010-00004","article-title":"Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable","volume":"155","author":"Connolly","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2019.10.008_bib22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.amjmed.2015.03.034","article-title":"Net clinical benefit of non-vitamin K antagonist oral anticoagulants versus warfarin in phase III atrial fibrillation trials","volume":"128","author":"Renda","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2019.10.008_bib23","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jacc.2013.05.042","article-title":"Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation","volume":"62","author":"Eikelboom","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2019.10.008_bib24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH11-05-0364","article-title":"Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study","volume":"106","author":"Olesen","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2019.10.008_bib25","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2019.10.008_bib26","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:28Z","timestamp":1758963088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0149291819305041"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}